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Summary
 
T cell receptor 
 
a
 
 chain–deficient (TCR-
 
a
 
2
 
/
 
2
 
) mice are known to spontaneously develop in-
flammatory bowel disease (IBD). The colitis that develops in these mice is associated with in-
creased numbers of T helper cell (Th)2-type CD4
 
1
 
TCR-
 
bb
 
 (CD4
 
1
 
bb
 
) T cells producing
predominantly interleukin (IL)-4. To investigate the role of these Th2-type CD4
 
1
 
bb
 
 T cells,
we treated TCR-
 
a
 
2
 
/
 
2
 
 mice with anti–IL-4 monoclonal antibody (mAb). Approximately 60%
of TCR-
 
a
 
2
 
/
 
2
 
 mice, including those treated with mock Ab and those left untreated, spontane-
ously developed IBD. However, anti–IL-4 mAb–treated mice exhibited no clinical or histo-
logical signs of IBD, and their levels of mucosal and systemic Ab responses were lower than
those of mock Ab–treated mice. Although TCR-
 
a
 
2
 
/
 
2
 
 mice treated with either specific or
mock Ab developed CD4
 
1
 
bb
 
 T cells, only those treated with anti–IL-4 mAb showed a de-
crease in Th2-type cytokine production at the level of mRNA and protein and an increase in
interferon 
 
g
 
–specific expression. These findings suggest that IL-4–producing Th2-type
CD4
 
1
 
bb
 
 T cells play a major immunopathological role in the induction of IBD in TCR-
 
a
 
2
 
/
 
2
 
mice, a role that anti–IL-4 mAb inhibits by causing Th2-type CD4
 
1
 
bb
 
 T cells to shift to the
Th1 type.
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Th2-induced colitis
 
T
 
he etiopathogenesis of inflammatory bowel disease
(IBD),
 
1
 
 a chronic and relapsing inflammation of the
gastrointestinal tract, remains poorly understood. In an ef-
fort to elucidate the molecular and cellular mechanisms be-
hind IBD (1–8), researchers in the last six years have used
several specific gene-manipulated animal models, including
TCR 
 
a
 
 chain–deficient (TCR-
 
a
 
2/2
 
) mice, TCR-
 
b
 
2/2
 
mice, MHC class II–deficient mice, IL-2–deficient mice,
IL-10–deficient mice, IL-7 transgenic mice, G
 
a
 
i2
 
-deficient
mice, and severe combined immunodeficiency (SCID)
mice restored with CD45RB
 
hi
 
CD4
 
1
 
 T cells. Of interest
here are the TCR-
 
a
 
2/2
 
 mice, which spontaneously de-
velop chronic colitis, a condition similar to ulcerative coli-
tis in humans (2, 9, 10). About 60% of TCR-
 
a
 
2/2
 
 mice
develop chronic diarrhea and anorectal prolapse under spe-
 
cific pathogen-free conditions at 
 
z
 
3–4 mo of age. Tissue
sections from the diseased colons of these animals show in-
filtration of inflammatory cells and elongation of crypts. In
addition, higher levels of Ab are found in the mucosa-asso-
ciated tissues (e.g., mesenteric lymph nodes [MLNs],
Peyer’s patches, and intestinal lamina propria [LP]) as well
as in the systemic lymphoid organs (e.g., spleen [SP]) of
these animals (9, 10).
Our own previous studies and those of other investiga-
tors have shown that CD4
 
1
 
TCR-
 
a
 
2
 
/
 
b
 
1
 
 (CD4
 
1
 
b
 
dim
 
) T
cells develop in the mucosal and peripheral lymphoid
tissues of TCR-
 
a
 
2
 
/
 
2
 
 mice with IBD (9–12). These
CD4
 
1
 
b
 
dim
 
 T cells are considered to be pathogenic for the
induction of IBD in this mouse model, since depletion of
CD4
 
1
 
b
 
dim
 
 T cells by anti–TCR-
 
b
 
 mAb prevents the onset
of IBD (10). The pathogenic nature of these CD4
 
1
 
b
 
dim
 
 T
cells is also evidenced by the lesser severity of IBD seen in
 
1
 
Abbreviations used in this paper:
 
 CD4
 
1
 
b
 
dim
 
, CD4
 
1
 
TCR-
 
a
 
2
 
/
 
b
 
1
 
;
CD4
 
1
 
bb
 
, CD4
 
1
 
TCR-
 
bb
 
; ELISPOT, enzyme-linked immunospot;
IBD, inflammatory bowel disease; LP, lamina propria; MLN, mesenteric
lymph node; RT, reverse-transcription; SP, spleen. 
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TCR-
 
b
 
2
 
/
 
2
 
 mice, from which CD4
 
1
 
b
 
dim
 
 T cells are absent
(2). Our previous study showed that CD4
 
1
 
b
 
dim
 
 T cells
produce a predominance of IL-4, suggesting a potential
role for Th2-type responses in the development of IBD
(10). However, the association between IL-4–producing
Th2-type CD4
 
1
 
b
 
dim
 
 T cells and IBD is still poorly under-
stood. Since our most recent study has provided strong ev-
idence that these CD4
 
1
 
b
 
dim
 
 T cells use a 
 
bb
 
 homodimeric
form of TCR, this subset of T cells will be designated here
as 
 
bb
 
 T cells in order to reflect the unique characteristics of
these pathologic lymphocytes (13).
In this study, TCR-
 
a
 
2
 
/
 
2
 
 mice were treated with either
anti–IL-4 mAb or mock Ab. In treated TCR-
 
a
 
2
 
/
 
2
 
 mice,
Ab responses in the serum and fecal extracts were strongly
suppressed and cytokine production from CD4
 
1
 
bb
 
 T cells
was shifted from the Th2 to the Th1 type. In addition,
morphological and histological studies showed no obvious
signs of IBD in TCR-
 
a
 
2
 
/
 
2
 
 mice treated with anti–IL-4
mAb. These findings provide new evidence that Th2-type
CD4
 
1
 
bb
 
 T cells can induce IBD. Conversion from a
dominant Th2 to a Th1 environment resulted in the pre-
vention of IBD in TCR-
 
a
 
2
 
/
 
2
 
 mice.
 
Materials and Methods
 
Mice.
 
TCR-
 
a
 
2
 
/
 
2
 
 mice with a background of C57BL/6 were
obtained from The Jackson Laboratory. The mice were originally
generated by a targeted disruption of TCR genes in embryonic
stem cells (2). They were housed in the Experimental Animal Fa-
cility at the Research Institute for Microbial Diseases, Osaka
University, under specific pathogen-free conditions and received
sterilized food and autoclaved distilled water ad libitum.
 
Anti–IL-4 mAb Treatment.
 
In this study, a standard protocol
was used for mAb in vivo treatment (10). TCR-
 
a
 
2
 
/
 
2
 
 mice from
6 to 25 wk of age were intraperitoneally injected with rat anti–
mouse IL-4 mAb (BVD4-1D11, 1 mg/mouse; PharMingen) or
rat IgG2b (R35-38, 1 mg/mouse; PharMingen) as mock Ab in
250 
 
m
 
l of PBS once a week. These treatments did not produce
any signs of serum sickness.
 
Detection of Abs by ELISA.
 
Levels of IgA, IgG, and IgM Ab
in serum and fecal extracts at 25 wk of age were examined by
ELISA as described previously (14). In brief, ELISA plates (Nunc)
were coated with 100 
 
m
 
l of 5 
 
m
 
g/ml goat anti–mouse Ig (H
 
1
 
L)
(Southern Biotechnology Associates) in PBS and were incubated
for 16 h at 4
 
8
 
C. Serial twofold dilutions of sera or fecal extracts
were added (100 
 
m
 
l/well). The fecal extracts were the superna-
tants obtained after fresh feces were mixed with PBS containing
0.5% sodium azide (100 mg wet weight of feces/ml) and then
centrifuged (15). After 2 h incubation at 37
 
8
 
C, unbound Abs
were removed, and alkaline phosphatase–conjugated goat or rat
anti–mouse 
 
a
 
, 
 
g
 
, and m chains (Southern Biotechnology Associ-
ates) were added. The plates were incubated at 378C for 2 h and
developed with p-nitrophenyl phosphate (1 mg/ml; Wako) in 10
mM diethanolamine buffer (pH 9.6). Ab concentrations were
calculated from the standard curve by using purified mouse IgA,
IgG, and IgM (Southern Biotechnology Associates). In addition,
subclass–specific IgG Ab titers were also analyzed by using alka-
line phosphatase–conjugated goat anti–mouse IgG1, IgG2a,
IgG2b, and IgG3 (Southern Biotechnology Associates) as detec-
tion Ab. Further, murine IgG1, IgG2a, IgG2b, and IgG3 anti-
bodies (Southern Biotechnology Associates) were used for the
generation of a standard curve.
Preparation of Cell Suspensions. Mice anesthetized with keta-
mine (Sigma Chemical Co.) were killed at 25 wk of age. The SPs
and MLNs were aseptically removed, and single-cell suspensions
were prepared by a standard mechanical procedure. Mononuclear
cells from the LP of the colon were dissociated using type IV col-
lagenase (Sigma Chemical Co.) to obtain single-cell preparations
as described previously (16).
Enzyme-linked Immunospot. Total IgA, IgG, and IgM Ab–
forming cells in SP, MLNs, and colonic LP were analyzed by an
enzyme-linked immunospot (ELISPOT) assay as described previ-
ously (10). Nitrocellulose microtiter plates (Millipore Co.) were
coated with 100 ml of anti–mouse IgA, IgG, or IgM (Southern
Biotechnology Associates) at a concentration of 5 mg/ml in PBS.
For the detection of Ab-producing cells, alkaline phosphatase–
conjugated anti–mouse IgA, IgG, or IgM (1 mg/ml; Southern
Biotechnology Associates) was added and then visualized with a
substrate. The substrate used was 5-bromo-4-chloro-3-indolyl
phosphate (Wako)/nitroblue tetrazolium (Wako) in alkaline phos-
phatase buffer (100 mM Tris-HCl [pH 9.5] containing 100 mM
NaCl and 5 mM MgCl2).
Flow Cytometric Analysis and Cell Sorting. For the analysis of
the profile of CD41bb T cells by flow cytometry, PE-conjugated
anti-CD4 (anti-L3T4; RM4-5) mAb and FITC-conjugated anti–
TCR-b mAb (H57-597) were obtained from PharMingen. Sin-
gle-cell suspensions of lymphocytes (106/sample) were then
stained with optimal concentrations of PE-conjugated anti-CD4
mAb and FITC-conjugated anti–TCR-b mAb. These samples
were subjected to flow cytometric analysis by using a FACScan™
(Becton Dickinson). Data were analyzed by using CellQuest soft-
ware (Becton Dickinson). For the analysis of the cytokine profile,
CD41bb T cells were purified by FACS Vantage™ (Becton
Dickinson).
Reverse-transcription PCR. Cytokine production by purified
CD41bb T cells from colonic LP was analyzed by modified cy-
tokine-specific reverse-transcription (RT)-PCR as described (17,
18). To isolate RNA from the CD41bb T cells purified by flow
cytometry, TRIzol reagent (GIBCO BRL) was used. Purified
RNA was reverse transcribed into cDNA using Superscript II re-
verse transcriptase (GIBCO BRL) and DIG DNA Labeling Mix®
(Boehringer Mannheim), which incorporates DIG-labeled dUTP
every 20–25 nucleotides during reverse transcription. The DIG-
labeled, synthesized cDNA and a series of diluted DIG-labeled
control cDNA (Boehringer Mannheim) were dot blotted onto
the nucleic acid transfer membrane (Amersham Pharmacia Bio-
tech) and cross-linked by UV cross-linker (Spectronics). The
membrane was subjected to blocking by 1% Blocking reagent®
(Boehringer Mannheim) in 0.15 M NaCl, 0.1 M maleic acid for
30 min, followed by an additional 30-min incubation with 7.5
U/liter of alkaline phosphatase–conjugated anti-DIG Abs (Boeh-
ringer Mannheim) in 1% Blocking reagent® (Boehringer Mann-
heim). The membrane was then incubated with 1% chemilumi-
nescent substrate for alkaline phosphatase, CDPstar™ (Tropix),
in 100 mM Tris-HCl, 100 mM NaCl, 50 mM MgCl2. The de-
veloped chemiluminescent signals on the membrane were ex-
posed to an imaging screen for 18 h, and then characterized by an
image analyzer (Molecular Imager® system; Bio-Rad Laborato-
ries). The images on the screen were extracted by a laser scanner,
and the number of synthesized cDNA samples were quantitated
using the image analyzer. PCR amplification of 10 ng of cDNA
for each sample was performed with the GeneAmp PCR System
9700 (Perkin-Elmer Cetus). The cytokine-specific primers and609 Iijima et al.
amplification protocols used have been described previously
(18). The amplified products were separated by electrophoresis
in 1.8% agarose gel and were visualized with ethidium bromide
(1 mg/ml).
Cytokine ELISA. Lymphocytes (106/well) isolated from co-
lonic LP of anti–IL-4 mAb– or mock Ab–treated mice were
stimulated in vitro with precoated purified anti–mouse CD3e
mAb (145-2C11, 10 mg/ml; PharMingen) or anti–mouse TCR-b
(H57-597, 10 mg/ml; PharMingen) in 24-well microplates for 72 h.
After the incubation period, the supernatants were collected to
analyze Th1 (IFN-g) and Th2 cytokine (IL-4 and IL-6) produc-
tion. Cytokine synthesis in the culture supernatants was analyzed
by using the Biotrak™ ELISA system (Amersham Pharmacia
Biotech) according to the manufacturer’s protocol.
Histological Analysis. Tissue samples were fixed in 4% para-
formaldehyde in PBS for 4 h, embedded in paraffin, and sec-
tioned at a thickness of 5 mm. Sections were stained by the con-
ventional hematoxylin and eosin staining method. The periodic
acid–Schiff–alcian blue procedure was also performed in order to
stain goblet cells (19).
Statistical Analysis. Data were statistically analyzed by the
Student’s  t test.
Results
Anti–IL-4 mAb Treatment Blocked Aberrant Ig Production in
TCR-a2/2 Mice. As increased levels of Abs are one of the
immunological features of TCR-a2/2 mice with IBD (10),
we sought to determine and compare the levels of serum
and fecal IgA, IgG, and IgM Abs in anti–IL-4 mAb– and
mock Ab–treated TCR-a2/2 mice at 25 wk of age by us-
ing ELISA. Serum as well as fecal Ab titers were increased
in mock Ab–treated TCR-a2/2 mice (Fig. 1 A). The lev-
els of Ab titers in these mice were comparable to those of
untreated mice, as observed in previous reports (9, 10).
However, the levels of IgA, IgG, and IgM Abs in serum
and fecal extracts were significantly decreased in TCR-a2/2
mice treated with anti–IL-4 mAb (P , 0.01; Fig. 1 A).
When IgG subclass Ab titers of TCR-a2/2 mice treated
with anti–IL-4 mAb were examined by ELISA, levels of
IgG1 and IgG2b were found to have decreased and those of
IgG2a to have increased significantly (P , 0.01; Fig. 1 B).
Inhibition of B Cell Development in TCR-a2/2 Mice by
Anti–IL-4 mAb Treatment. To further confirm the reduc-
tion of Ab production at the cellular base, mononuclear
cells were isolated from systemic and mucosal tissues of
TCR-a2/2 mice treated with anti–IL-4 mAb and mock
Ab for subsequent ELISPOT assay. The numbers of Ab-
forming cells were increased in the systemic lymphoid
(e.g., SP) as well as in mucosa-associated tissues (e.g.,
MLNs, colonic LP) of TCR-a2/2 mice treated with mock
Ab (Fig. 2). On the other hand, numbers of IgA, IgG, and
IgM Ab–forming cells from TCR-a2/2 mice treated with
anti–IL-4 mAb were significantly decreased both in the sys-
temic lymphoid and mucosa-associated tissues (P , 0.01;
Fig. 2).
Anti–IL-4 mAb Did Not Influence the Development of
CD41bb T Cells. Since the administration of anti–IL-4
mAb inhibited Ab production in TCR-a2/2 mice (Figs. 1
and 2), we next used flow cytometry to assess the influence
of mAb treatment on the development of CD41bb T cells.
A subset of CD41bb T cells costained with PE-conjugated
anti-CD4 mAb (RM4-5) and FITC-conjugated anti-
TCR-b (H57-597) was detected in the mucosal and
peripheral tissues of mock Ab–treated TCR-a2/2 mice.
Surprisingly, a similar frequency of CD41bb T cells also
developed in TCR-a2/2 mice treated with anti–IL-4 mAb
(Fig. 3). Additionally, the number of total lymphocytes in
colonic LP obtained by dissociation with collagenase
showed no statistical change between the two groups of
mice (Mock Ab, 4.4 6 0.8 3 106 cells/mouse; and anti–
IL-4 mAb, 4.0 6 0.6 3 106 cells/mouse). Further, mice
treated with anti–IL-4 mAb did not show obvious clinical
signs of IBD (see section below). These findings show that
Figure 1. Comparison of Ig levels in serum and fecal extracts of TCR-
a2/2 mice treated with anti–IL-4 mAb (hatched bars) or rat IgG2b (mock
Ab, black bars). (A) The levels of IgA, IgG, and IgM Abs in serum and
fecal extracts were analyzed by ELISA. (B) The levels of IgG subclass Ab
were also analyzed by ELISA. Data represent the mean 6 SEM from
eight mice per group. *Significantly different from each other (P , 0.01)
by Student’s t test.610 Inhibition of IL-4 Synthesis Prevents Th2 Cell–induced IBD
anti–IL-4 mAb treatment did not influence the develop-
ment of CD41bb T cells.
Anti–IL-4 mAb Treatment Altered the Cytokine Profile of
CD41bb T Cells from Dominant Th2 to Th1 Type. As the
development of aberrant CD41bb T cells was not affected
by treatment with anti–IL-4 mAb (Fig. 3), we next ana-
lyzed the cytokine profile of CD41bb T cells isolated from
TCR-a2/2 mice treated with anti–IL-4 mAb or mock Ab.
The CD41bb T cells were isolated from the colonic LP of
TCR-a2/2 mice by FACS Vantage™, and the profile of
Th1 and Th2 cytokine expression was examined by cyto-
kine-specific RT-PCR. Our previous study showed that
CD41bb T cells could be considered to be of the Th2
phenotype, since a cytokine-specific ELISPOT assay
showed that they produced IL-4 but not Th1 cytokines
(10). This pattern of Th2-type cytokine production was
also confirmed by cytokine-specific RT-PCR, since
CD41bb T cells isolated from the colonic LP of mock Ab–
treated TCR-a2/2 mice expressed mRNA specific for IL-4,
IL-5, IL-6, and IL-10, but not for Th1-type cytokines (Fig.
4). Conversely, in the TCR-a2/2 mice treated with anti–
IL-4 mAb, the pattern of cytokine production was signifi-
cantly changed; namely, specific messages for Th2-type cy-
tokines such as IL-4, IL-5, and IL-10 were not detected,
whereas those for Th1-type cytokines (e.g., IFN-g) were
upregulated (Fig. 4). In addition, the analysis of CD41bb
T cells isolated from the MLNs of IL-4–specific mAb–
treated mice resulted in the alteration of cytokine expres-
sion from a dominant Th2 to a Th1 type. The reduction of
Th2-type cytokine production and the enhancement of
Th1-type cytokine production in mice treated with anti–
IL-4 mAb were further confirmed at the protein level
through ELISA analysis of secreted Th1 and Th2 cytokines
(Fig. 5). Thus, in vitro stimulation of colonic lymphocytes
isolated from anti–IL-4 mAb–treated mice with anti-CD3e
or anti–TCR-b resulted in the decrease of Th2 cytokines
(e.g., IL-4 and IL-6) and the increase of IFN-g synthesis.
In contrast, treatment with mock Ab resulted in high levels
of Th2 cytokine production. These results demonstrate that
a shift from a Th2- to Th1-type response was induced in
anti–IL-4 mAb–treated TCR-a2/2 mice.
Alteration of the Aberrant Immune Response by Anti–IL-4
mAb Treatment Resulted in the Prevention of Mucosal Inflamma-
tion in TCR-a2/2 Mice. We next investigated the effect
Figure 2. Enumeration of Ab-producing
cells in systemic and mucosal lymphoid tis-
sues from mice treated with anti–IL-4 mAb
(hatched bars) or mock Ab (black bars).
Mononuclear cells isolated from SP, MLNs,
and colonic LP (LPL) of TCR-a2/2 mice
treated with anti–IL-4 mAb or rat IgG2b
(mock Ab) were examined by isotype-spe-
cific ELISPOT. Data represent the mean 6
SEM from five mice per group of three sepa-
rate experiments. *Significantly different
from each other (P , 0.01) by Student’s t test.
Figure 3. Flow cytometric analysis of CD41bb T cells in the colonic
LP of TCR-a2/2 mice treated with/without anti–IL-4 mAb. Mononu-
clear cells from the colonic LP of TCR-a2/2 mice treated with anti–IL-4
mAb or mock Ab were isolated and costained with anti-CD4 (L3T4) and
anti–TCR-b (H57-597) mAbs. Flow cytometric analysis was performed
by FACScan™.
Figure 4. Cytokine-specific mRNA expression by CD41bb T cells in
the mucosal compartment of TCR-a2/2 mice treated with or without
anti–IL-4 mAb. CD41bb T cells in the MLNs and colonic LP of TCR-
a2/2 mice treated with anti–IL-4 mAb (A) or mock Ab (M) were puri-
fied by flow cytometry, and cytokine-specific mRNA expression was an-
alyzed by Th1 and Th2 cytokine-specific RT-PCR. The far left column
(MW) shows a 1-kb DNA ladder.611 Iijima et al.
of anti–IL-4 mAb on the induction of IBD in the TCR-
a2/2 mice. Approximately 60% of TCR-a2/2 mice
treated with mock Ab or left untreated were observed to
develop the morphological changes that have been re-
ported previously to be typical of IBD, including anorectal
prolapse, diarrhea, and the weight loss and hunched posture
characteristic of wasting syndrome (2, 10). In contrast, the
mice treated with anti–IL-4 mAb showed no significant
weight loss (Fig. 6). Histological examination of the intesti-
nal LP of TCR-a2/2 mice treated with anti–IL-4 mAb
showed more elongation of epithelial villi and markedly
less infiltration of inflammatory cells than in that of mice
treated with mock Ab (Fig. 7). Because a reduction in the
number of goblet cells has also been reported in the colon
of humans with IBD (20), we stained tissue sections pre-
pared from the colon of anti–IL-4 mAb– and mock Ab–
treated TCR-a2/2 mice with alcian blue in order to detect
goblet cells. As in the colons of humans suffering from
IBD, the number of goblet cells in colons of mock Ab–
treated mice was reduced. In contrast, the number of gob-
let cells was almost normal in the colon of TCR-a2/2
mice treated with anti–IL-4 mAb (Fig. 8). These findings
suggest that the inhibition of the Th2-type response by
anti–IL-4 mAb treatment results in the prevention of mu-
cosal inflammation in TCR-a2/2 mice.
Discussion
The mucosal immune system consists of several immune
components, including a/b and g/d T cells, IgA B cells,
macrophages, dendritic cells, and epithelial cells, that form
a molecular and cellular inter/intranet that provides a pro-
tective barrier against pathogens and environmental anti-
gens in the gut (21–23). Under normal conditions, the mu-
cosal immune system also properly regulates the intestinal
mucosa. However, in those suffering from IBD, the mucosal
immune system, and more particularly the T cell–dependent
regulatory system, is disrupted (1, 3). In TCR-a2/2 mice,
CD41bb T cells are considered to play a key role in the in-
duction of IBD (9, 10, 13).
The results of this study demonstrated two new and im-
portant points regarding the role of Th1- and Th2-type
cells in the development of IBD. In all murine IBD models
used, including specific gene-manipulated and hapten-
induced mice, a common observation was that the en-
hancement of Th1-type activity was associated with disease
development (24–26). However, previous studies have
posited that Th2-like responses are involved in the devel-
opment of colon inflammation in human ulcerative colitis
(27–31). Our study directly demonstrates that CD41bb T
cells isolated from the inflamed colon possess characteristics
of Th2-type cells based on their cytokine profile at the
mRNA and protein levels (Figs. 4 and 5). Further, it was
shown that alteration of the cytokine profile from a Th2 to
a Th1 type by treatment with anti–IL-4 mAb resulted in
the prevention of colitis in TCR-a2/2 mice (Figs. 4 and
5). The decrease of IL-4–dependent IgG1 and IgG2b Ab
responses further confirmed that anti–IL-4 mAb treatment
inhibited Th2-type responses (Fig. 1 A). These two impor-
tant findings suggest that aberrant mucosal Th2-type cells
are involved in the development of chronic inflammation
in the intestinal tract. Two very recent studies support this
conclusion by demonstrating that Th2-type CD41 T cells
play a major role in the development of hapten-induced
murine colitis (32, 33).
IL-4 initially received attention as an enhancer of DNA
synthesis in mouse B lymphocytes (34). Since then, exten-
sive molecular and immunological investigations have es-
tablished IL-4 as a biologically potent and essential cyto-
kine for B cell development and responses, including those
of IgE and IgG1 (35). Further, this cytokine has been
Figure 5. Cytokine production by colonic lymphocytes isolated from
mice with anti–IL-4 mAb (hatched bars) or mock Ab (black bars) treat-
ment. Colonic lymphocytes were stimulated in vitro with precoated anti-
CD3e mAb (a-CD3) or anti–TCR-b mAb (a-TCRb) for 72 h. Culture
supernatants were then collected and cytokine production was analyzed
by cytokine ELISA. Data represent the mean 6 SEM from two mice per
group of three different experiments.
Figure 6. Body weight of TCR-a2/2 mice treated with/without anti–
IL-4 mAb treatment. Body weight of TCR-a2/2 mice treated with anti–
IL-4 mAb (BVD4-1D11) or mock Ab (R35-38) was measured weekly
for 25 wk. Data represent the mean 6 SEM of eight mice per group.612 Inhibition of IL-4 Synthesis Prevents Th2 Cell–induced IBD
shown to play an essential role in the generation of Th2-
type from Th0-type cells (35). Although IL-4 is considered
to be a hallmark cytokine for Th2-type T cells, it should be
noted that other immunologically competent cells such as
mast cells, basophils, g/d T cells, and NK1.11 T cells can
produce this cytokine (35–40). NK1.11CD41 T cells have
been shown to be a particularly important source of IL-4
(37). Histological analysis with alcian blue and flow cyto-
Figure 7. Histological analysis
of TCR-a2/2 mice treated with
or without anti–IL-4. Rectums
of TCR-a2/2 mice treated with
anti–IL-4 mAb or mock Ab
were resected and routine histol-
ogy, including fixing with for-
malin, embedding in paraffin,
and staining with hematoxylin
and eosin, was performed.
Figure 8. Histological analysis
of goblet cells in the intestinal
epithelium of TCR-a2/2 mice
treated with or without anti–IL-4.
Rectums of TCR-a2/2 mice
treated with anti–IL-4 mAb or
mock Ab were resected and the
periodic acid–Schiff–alcian blue
procedure was performed, which
includes fixing with formalin,
embedding in paraffin, and stain-
ing with periodic acid–Schiff–
alcian blue.613 Iijima et al.
metric analysis using mAb specific to NK1.1 detected only
a small number of mast cells and NK1.11 T cells in TCR-
a2/2 mice (data not shown). Although our previous and
present results clearly demonstrate that CD41bb T cells are
the primary source for the production of IL-4 in TCR-a2/2
mice with IBD, it is still possible that a minor population of
NK1.11CD41 T cells provides an alternative source of the
cytokine. When mucosal g/d T cells were isolated from
the intestinal tract of TCR-a2/2 mice with IBD for the
analysis of cytokine production, no specific message for IL-4
was detected (data not shown). Therefore, the population
of CD41bb T cells is most likely the major source of IL-4.
In regard to the increased B cell responses in these dis-
eased TCR-a2/2 mice, Th2 cytokines produced by
CD41bb T cells are responsible for the activation of auto-
and food antigen–specific IgG, IgE, and IgA Ab production
pathways (10). IL-4 is a well-known switch factor for IgE
and IgG1 induction (35). In addition to auto- and food an-
tigen-specific IgG1 and IgE responses, IgA Ab responses
were also upregulated in TCR-a2/2 mice with IBD (10).
A similar pattern of response was also observed in TCR-
a2/2 mice treated with mock Ab. The increased B cell re-
sponses in TCR-a2/2 mice with IBD could be explained
by our present finding that these CD41bb T cells were ca-
pable of producing IL-5, IL-6, and IL-10 in addition to IL-4
(Fig. 4). These Th2-type cytokines further support the pro-
duction of Abs, including those of the IgA isotype, in
TCR-a2/2 mice. In fact, studies using both murine and
human experimental systems have shown that IL-5, IL-6,
and IL-10 are IgA-enhancing cytokines (20, 21). When
TCR-a2/2 mice were treated with anti–IL-4 mAb, the
levels of all the isotypes of Abs were significantly decreased
in their serum and fecal extracts. Inasmuch as our results
demonstrated that anti–IL-4 mAb treatment altered the cy-
tokine profile of CD41bb T cells from a Th2 to a Th1
type (Figs. 4 and 5), it is most likely that an abrogation of
Th2 cytokine synthesis resulted in the reduction of B cell
development.
It is not yet known whether Abs against auto- and food
antigens play a pathological role, much less by what means
they might do so. Several reports have provided evidence
that the levels of autoantibodies (autoAbs, e.g., anti-goblet
cell, antitropomyosin, and anticolon autoAbs) were in-
creased in the colon of humans suffering from IBD and
have suggested that these autoAbs are the causative patho-
gens for the destruction of mucosal tissues by Ab-depen-
dent cell-mediated cytotoxicity (40–44). Therefore, one
possible mechanism for the prevention of IBD by anti–IL-4
mAb could be the reduction of autoAb-producing B cell
responses. However, a separate study demonstrated that the
disease process accelerated in double knockout mouse,
which lacked both Ig m and TCR a chains and which
were generated by crossing TCR-a2/2 and Ig-m–deficient
mice (45). It also showed that, in some cases, the removal
of B cells worsened the symptoms of colitis. The results of
that study suggest that Abs play a protective rather than a
pathological role in the development of mucosal inflamma-
tion. It remains to be examined whether aberrant B cells
and their derived Abs are involved in the initiation of the
inflammatory process in IBD.
IL-4 has been shown to directly regulate intestinal epi-
thelial cell functions. For example, IL-4 can regulate the
growth of epithelial cells. It is also capable of disrupting the
barrier function of the intestinal epithelium, of enhancing
the adherence of neutrophils to the epithelia, and of upreg-
ulating transepithelial neutrophil migration (46). Overpro-
duction of IL-4 in the intestinal epithelium may disrupt
immunological homeostasis between the mucosal immune
system and environmental antigens, including gut lumen
microorganisms, allowing recruitment of inflammatory
cells for the initiation of disease. Therefore, a second possi-
ble mechanism for the prevention of colitis development
by mAb treatment might be the direct inhibition of IL-4
effects on the intestinal epithelial cells.
IL-4–specific mAb treatment directly inhibited the de-
velopment of Th2-type aberrant CD41bb T cells, which
are thought to be directly involved in the induction of
IBD. For example, Th2-dominated conditions such as
those characteristic of IFN-g2/2 mice have been shown to
be conducive to the development of a delayed-type hyper-
sensitivity reaction (47, 48), and Th2-type cells are thought
to contribute to the development of autoimmune diseases
(49, 50). Finally, a recent study from another group pro-
vided direct evidence that IL-4 produced by Th2-type
CD41bb T cells was associated with the development of
murine colitis by showing the reduction of disease inci-
dence in mice of the TCR-a2/2 and IL-42/2 double
knockout models (51).
In summary, this study has demonstrated that the patho-
logical ability of CD41bb T cells to induce IBD is inhib-
ited by their alteration from a Th2 to a Th1 type. It has also
shown that the treatment of TCR-a2/2 mice with anti–
IL-4 mAb resulted in the blockage of colitis formation.
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